Singulair® oral granules
This product is taken orally.
Why is it prescribed?
Montelukast is indicated in adult and children 2 years of age and older for the prevention and chronic treatment of asthma, including prevention of day- and night- time symptoms, the treatment of acetylsalicylic acid (ASA)- sensitive asthmatic patients, and the prevention of exercise- induced bronchoconstriction.
Montelukast is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montelukast and inhaled corticosteroids may be used together to control asthma or to reduce the inhaled corticosteroid dose.
In patients who continue to experience asthma symptoms, Montelukast can be an additional treatment option following initial management with an as needed short-acting bronchodilator (SABA), an inhaled corticosteroid, or inhaled corticosteroid together with a long-acting bronchodilator.
In adults, Montelukast can be a treatment option after as needed SABAs if patients remain symptomatic and cannot or will not use an inhaler device or would prefer not to be treated with an inhaled corticosteroid.
In children, Montelukast can be a treatment option after as needed SABAs if patients remain symptomatic and cannot appropriately use an inhaler device.
Montelukast can be a treatment option in patients who experience exercise-induced bronchoconstriction.
Montelukast is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 15 years old or older. Montelukast should be considered when other treatments are not effective or not tolerated
- Singulair® oral granules can be administered either directly in the mouth, or mixed with a spoonful of cold or room temperature soft food (e.g., apple sauce). The packet should not be opened until ready to use. After opening the packet, the full dose of Singulair® oral granules must be administered immediately (within 15 minutes). If mixed with food, Singulair® oral granules must not be stored for future use. Singulair® oral granules are not intended to be dissolved in liquid for administration. However, liquids may be taken subsequent to administration. Since Singulair® is used to prevent asthma attacks, it should be given regularly as prescribed even when your child is not experiencing asthma symptoms.
- Keep a diary of the time, frequency, and severity of your child's asthma attacks for the first three months after starting Singulair®. This will help your doctor assess how well your child is responding to the new medication and assist the doctor in adjusting the therapy for maximum benefit.
- Singulair® should be given once daily at bedtime with or without food.
- It is important not to adjust your child's dosage without first consulting your doctor. If a dose is missed, ignore the missed dose and take the next dose at the scheduled time. Never take two doses at once.
- Store Singulair® in the original package at room temperature (15 to 30 degrees Centigrade) in a dry place.
Other products that have the same ingredient as Singulair® oral granules are •ACH-montelukast tablets •Apo-Montelukast tablets •Auro-Montelukast tablets •Jamp-Montelukast tablets •MAR-montelukast tablets •Mint-Montelukast tablets •Montelukast chewable tablets •Montelukast tablets •PMS-Montelukast chewable tablets •PMS-Montelukast tablets •Riva-Montelukast tablets •Sandoz Montelukast chewable tablets •Sandoz Montelukast oral granules •Sandoz Montelukast tablets •Sanis-Montelukast tablets •Singulair® chewable tablets •Singulair® oral tablets •Sivem-Montelukast tablets •Teva-Montelukast chewable tablets •Teva-Montelukast tablets •
The recommended dose of Singulair® oral granules for children 2 to 5 years of age is one packet (4 mg) once daily in the evening.
Montelukast is a leukotriene receptor antagonist that blocks substances in the lungs called leukotrienes. Leukotrienes cause narrowing and swelling of airways in the lungs. Blocking leukotrienes improves asthma symptoms and helps prevent asthma attacks.
Along with its needed effects, montelukast may cause some unwanted or undesirable effects. Generally, montelukast is well tolerated and many people will not experience unwanted effects. The frequency and severity of these effects is dependant on many factors including dose, duration of therapy and individual susceptibility. Possible unwanted effects include:
- stomach pain
- skin rash
If these symptoms persist, are very troublesome, or if any unusual symptom appears consult with your pharmacist or doctor.
Very rarely, more serious adverse effects may occur. These include:
- agitation including aggressive behavior (including temper tantrums in pediatric patients), very rarely reported as serious; anxiousness, depression, irritability, restlessness, sleep disorders including dream abnormalities and insomnia, suicidal thinking and behavior (suicidality), tremor, visual hallucinations.
- increased bleeding tendency
- dizziness, drowsiness, and very rarely seizure
- nose bleeds
- diarrhea, stomach upset, nausea, vomiting
If any of the above, rare adverse reactions occur, they should be reported to your doctor.
It is important to understand that montelukast is not a bronchodilator and should not be used as rescue medication in acute asthmatic episodes. You should have a short-acting bronchodilator (e.g. salbutamol) available for rescue purposes.
Montelukast can be used alone or with inhaled and oral cortiosteroids (e.g. fluticasone) to prevent asthma attacks.
Do not stop taking or reduce the dosage of your other asthma medications without consulting your doctor.
Some people taking montelukast may be able to reduce or stop corticosteroid medication. If your doctor decides this is appropriate for you, reduce your corticosteroid dose gradually and report any increase in asthma symptoms to your doctor immediately.
Drug Interactions: To date, there have been no reports of drug interactions involving montelukast. However, it is still important that you inform your doctor and pharmacist of all the prescription and over-the counter medications that you are taking.
Use is not recommended in the following situations:
- allergy to montelukast or any component of the formulation
Caution is recommended in the following situations:
- severe liver disease
- phenylketonuria (chewable tablets only)
Use in pregnancy: Human data is limited. Although usually considered safe for use in pregnancy, consult your doctor or pharmacist before use.
Use while breastfeeding: It is not known whether or not montelukast is passed into breast-milk. Consult your doctor or pharmacist before using montelukast while breastfeeding.